End-of-day quote
Wiener Boerse
23:00:00 25/06/2024 BST
5-day change
1st Jan Change
84.15
EUR
+1.02%
-2.04%
+38.63%
Sales 2024 *
819M
878M
69.46B
Sales 2025 *
907M
972M
76.92B
Capitalization
4.54B
4.86B
385B
Net income 2024 *
170M
182M
14.41B
Net income 2025 *
212M
227M
17.97B
EV / Sales 2024 *
5.5
x
Net cash position
2024
*
34.15M
36.58M
2.9B
Net cash position
2025
*
147M
158M
12.47B
EV / Sales 2025 *
4.84
x P/E ratio 2024 *
27.2
x
P/E ratio 2025 *
22
x
Employees
1,925
Yield 2024 *
1.3%
Yield 2025 *
1.53%
Free-Float
35.68%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Rovi receives non-binding offers for manufacturing business
06-26
RE
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-08
CI
Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment
04-02
MT
Rovi, Partners to Form Entity for Advanced Therapies R&D
03-12
MT
Rovi explores sale of unit that makes drugs for third parties
03-07
RE
Rovi Responds to Press Speculation Regarding Contract Development Business Deal
03-07
MT
Transcript : Laboratorios Farmaceuticos Rovi, S.A., 2023 Earnings Call, Feb 27, 2024
02-27
The Ibex-35 opts for caution as corporate results continue to trickle in.
02-27
RE
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023
02-25
CI
US FDA finds control lapses at Moderna manufacturing plant
12-15
RE
Italy, Spain stocks hit peaks after over 20% rally in 2023
11-30
RE
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023
11-08
CI
Transcript : Laboratorios Farmaceuticos Rovi, S.A., H1 2023 Earnings Call, Jul 26, 2023
26/07/23
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023
26/07/23
CI
Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021.
26/07/23
CI
More news
OPINIONI DEGLI ANALISTI DEL GIORNO : Brunello Cucinelli, Brembo, Terna, Maire, Ferragamo, Rovi, Saes, Repsol, Hermes, Airbus, ASML, Amazon, Shell, Wise, Adidas, EQT...
06-28
Bolsa de Madrid: ¿Le apetece un poco más de inflación?
06-28
OPINIONES DE LOS ANALISTAS DEL DÍA : Fluidra, Sacyr, Merlin, Grifols, Enagás, Ence Energía, Safran, STMicroelectronics, Adyen, Swatch...
06-27
AVIS D'ANALYSTES DU JOUR : Safran, STMicroelectronics, Unibail, Sartorius Stedim Biotech, Alfen, Adyen, Swatch...
06-27
OPINIONI DEGLI ANALISTI DEL GIORNO : Brunello Cucinelli, Fincantieri, Saipem, Stellantis, Merlin, Grifols, Safran, STMicroelectronics, Adyen, Rio Tinto, Swatch...
06-27
More news 1 day +1.02%
1 week -2.04%
Current month -4.38%
1 month -5.98%
3 months +5.65%
6 months +40.60%
Current year +38.63%
More quotes
Managers
Title Age Since
Chief Executive Officer
-
31/12/93
Director of Finance/CFO
-
31/12/99
Chief Tech/Sci/R&D Officer
-
-
Members of the board
Title Age Since
Director/Board Member
-
31/12/94
Director of Finance/CFO
-
31/12/99
Chief Executive Officer
-
31/12/93
More insiders
Date
Price
Change
26/06/24
84.15
+1.02%
25/06/24
83.3
-0.24%
24/06/24
83.5
-2.79%
21/06/24
85.9
+1.18%
20/06/24
84.9
+0.24%
End-of-day quote
Wiener Boerse, June 25, 2024
More quotes
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows:
- pharmaceutical products manufactured under contract (49%);
- prescription pharmaceuticals (45%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.;
- diagnostic products (6%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals.
Net sales break down by source of revenue between sales of products (50.6%), sales of services (49.3%) and sales of licenses (0.1%).
Net sales are distributed geographically as follows: Spain (33%), European Union (17.3%), OECD countries (45.9%) and other (3.8%).
More about the company
Last Close Price
87.55
EUR
Average target price
94.81
EUR
Spread / Average Target
+8.30%
Consensus
1st Jan change
Capi.
+55.32% 815B -6.75% 352B +13.56% 314B +10.68% 303B +16.57% 242B +2.04% 224B +13.31% 218B +8.48% 168B -2.81% 159B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1